Uzatresgene autoleucel

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameUzatresgene autoleucel

Drug Alias Nameuza-celADP‑A2M4CD8

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy +[4]

Mechanisms of ActionMelanoma-associated antigen 4 modulators

TargetsMelanoma-associated antigen 4

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursHead and Neck Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAdaptimmune Llc

China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Llc Galapagos Nv Us Worldmeds

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsGastroesophageal Junction NeoplasmsHead and Neck NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeN/A